CSL share price lifts as plasma collections continue recovery

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

The CSL Ltd (ASX: CSL) share price is in the green today after the company presented at the 2022 Macquarie Australia Conference in Sydney.

CSL shares are currently swapping hands at $275.38, a 1.82% gain. In contrast, the S&P/ASX 200 Index (ASX: XJO) is 0.1% lower at the time of writing.

Let’s take a look at what CSL reported today.

Why is the CSL share price lifting?

CSL informed the market that plasma collections are now at roughly the same level as prior to the COVID-19 pandemic.

In a presentation at the Macquarie conference, CSL also advised the company’s gross margin is predicted to return to pre-COVID levels in the future. CSL is working on technology improvements to plasma collection, reducing donation time by 30%.

CSL reported capital expenditure (CAPEX) is expected to be about $1.2 billion in FY22.

The company also highlighted the benefits of the Vifor Pharma acquisition. CSL is expecting regulatory approvals and closure on this deal by mid-2022.

CSL conducted a $750 million share plan for the acquisition in February, receiving strong support.

The CSL share price climbed nearly 2% in April amid multiple positive broker notes. Citi has placed a $335 price target on the company’s share price. This is nearly a 22% upside on the current share price.

CSL is predicting a net profit after tax (NPAT) of between $2.15 to $2.25 billion in FY22.

CSL share price snapshot

The CSL share price has climbed 1.55% in the past year but it has fallen more than 5% year to date.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 5% over the past year.

CSL has a market capitalisation of about $132.6 billion based on today’s share price.

The post CSL share price lifts as plasma collections continue recovery appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/GsYB1Q9

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s